Expression of bcl-2 and the progression of human and rodent prostatic cancers

Clinical Cancer Research

Volumn 2, Issue 2, 1996, Pages 389-398

  Furuya, Yuzo ^a   Krajewski, Stanislaw ^c   Epstein, Jonathan I ^b   Reed, John C ^c   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ANIMAL CELL; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RAT; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL DIVISION; DNA FRAGMENTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; TRANSFECTION;

EID: 0029983253     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Kyprianou, N., and Isaacs, J. T. Activation of programmed cell death in the rat ventral prostate following castration. Endocrinology, 122, 552-562, 1988.
2. Kyprianou, N., English, H., and Isaacs, J. T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3752, 1990.
3. Berges, R. S., Furuya, Y , Jacks, T., English, H., and Isaacs, J. T Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA, 90: 8910-8914, 1993.
4. Furuya, Y., and Isaacs, J. T. Proliferation independent cell death as a therapeutic target for prostatic cancer. Cancer Bull., 46: 173-180, 1994.
5. Furuya, Y., Lin, X. S., Walsh, I. C., Nelson, W. G., and Isaacs, J. T. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology, 136: 1898-1906, 1995.
6. Kyprianou, N., and Isaacs, J. T. Expression of transforming growth factor β in the rat ventral prostate during castration-induced programmed cell death. Mol. Endocrinol., 3: 1515-1522, 1989.
7. Furuya, Y., and Isaacs, J. T. Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation. Endocrinology, 133: 2660-2666, 1993.
8. 2+-dependent endonuclease as an early event in castration induced prostatic cell death. Prostate. 13: 103-117, 1988.
9. Martikainen, P., and Isaacs, J. T. The role of calcium in the programmed death of rat prostatic glandular cells. Prostate, 17: 175-188, 1990.
10. Carter, H. B., and Isaacs, J. T. Experimental and theoretical basis for hormone treatment of prostatic cancer. Semin. Urol., VI: 262-268, 1988.
11. Kyprianou, N., and Isaacs, J. T. "Thymineless" death in androgen-independent prostatic cancer Cells Biochem. Biophys. Res. Commun., 165: 73-81, 1989.
12. Martikainen, P., Kyprianou, N., Tucker, R. W., and Isaacs, J. T. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res., 51: 4693-4700, 1991.
13. Crawford, E. D., Eisenberger, M. A., McLeod, D. C., Spaulding, J., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A control randomized trial of leuprolide with and without flutamide in prostatic cancer. N. Engl. J. Med., 321: 419-424, 1989.
14. Furuya, Y., and Isaacs, J. T. Proliferation dependent versus independent programmed cell death of prostatic cancer cells involving distinct gene regulation. Prostate, 25: 301-309, 1994.
15. Furuya, Y., Lundmo, P., Short, A. D., Gill, D. L., and Isaacs, J. T. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res., 54: 6167-6175, 1994.
16. Goulian, M., Bleile, B. M., Dickey, L. M., Grafstrom, R. H., Ingraham, H A., Neynaber, S. A., Peterson, M. S., and Tseng, B. Y. Mechanism of thymineless death. Adv. Exp. Med. Biol., 195: 89-95, 1986
17. Canman, C. E., Lawrence, T. S., Shewach, D. S., Tang, H-Y., and Maybaum, J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res., 53: 5219-5224, 1993.
18. Isaacs, J. T., and Lundmo, P. Chemotherapeutic induction of programmed cell death in non-;Proliferating prostate cancer cells. Proc. Am. Assoc. Cancer Res., 33: 588-589, 1992.
19. Tsujimota, Y , Cossman, J., Jaffe, E., and Croce, C. Involvement of the bcl-2 gene in human follicular lymphoma. Science (Washington DC), 228: 1440-1443, 1985.
20. Chen-Levy, S., and Cleary, M. L. Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J. Biol. Chem., 265: 4929-4933, 1990.
21. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W , and Reed, J. C. Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res., 53: 4701-4714, 1993.
22. Reed, J. C. Cuddy, M., Slabiak, T., Croce, C. M., and Nowell, P. C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature (Lond.), 336: 259-261, 1988.
23. McDonnell, T. J. Deane, N., Platt, F. H., Nunes, G., Jaeger, U., McKearn, J. P., and Korsmeyer, S. J. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell, 57: 79-88, 1989.
24. Vaux, D., Cory, S., and Adams, J. Bcl-2 promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond.), 335: 440-442, 1988.
25. Hockenbery, D., Nuñez, G., Milliman, C , Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
26. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death, Cell, 74: 609-619, 1993.
27. Yin, X-M., Oltvai, Z. N., and Korsmeyer, S. J. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature (Lond.), 369: 321-323, 1994.
28. Miyashita, T., and Reed, J. C. Bcl-2 gene transfer increase relative resistance of S49.1 and WEHI7,2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
29. Miyashita, T., and Reed, J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 81: 151-157, 1993.
30. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 1853-1861, 1993.
31. Hanada, M., Krajewski, S., Tanaka, S., Cazals-Hatem, D., Spengler, B. A., Ross, R. A., Biedler, J. L., and Reed, J. C. Regulation of bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells. Cancer Res., 53: 4978-4986, 1993.
32. Levine, B., Huang, Q., Isaacs, J. T., Reed, J. C. Griffin, D. E., and Hardwick, J. M. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature (Lond.), 361: 739-742, 1993.
33. McDonnell T J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W. K., Hsieh, J-T., Tu, S-M., and Campbell, M. L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
34. Colombel, M., Symmans, F , Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S., and Buttyan, R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am. J. Pathol., 143: 390-400, 1993.
35. Shabaik, A. S., Krajewski, S., Burgan, A., Krajewski, M., and Reed, J. C. bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J. Urol. Pathol., 3: 17-27, 1995.
36. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
37. Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G., and Reed, J. C. Immunohistochemical determination of in vivo distribution of BAX, a dominant inhibitor of bcl-2. Am. J. Pathol., 145: 1323-1336, 1994.
38. Isaacs, J. T., and Hukku, B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate. 13: 165-188, 1988.
39. Isaacs, J. T., Isaacs, W. B., Feitz, W. F. J., and Scheres, J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate, 9: 261-281, 1986.
40. Hilton, J. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem. Pharmacol., 33: 1867-1872, 1984.
41. Stamato, T. D., and Denko, N. Asymmetric field inversion gel electrophoresis, a new method for detecting DNA double-strand breaks in mammalian cells. Radiat. Res., 121: 196-205, 1990.
42. Reed, J. C., Meister, Ly, Tanaka, S., Cuddy, M., Yum, S, Geyer, C., and Pleasure, D. Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res., 51: 6529-6538, 1991.
43. Bostwick, D. G. Prostatic intraepithelial neoplasia (PIN): current concepts. J. Cell. Biochem., (Suppl. 16H): 10-19, 1992.
44. Isaacs, J. T., Wake, N., Coffey, D. S., and Sandberg, A. A. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res., 42: 2353-2361, 1982.
45. Humphries, J. E., and Isaacs, J. T. Unusual androgen sensitivity of the androgen-independent Dunning R-3327 G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Cancer Res., 42: 3148-3156, 1982.
46. Isaacs, J. T. Role of Androgens in Prostatic Cancer. Vitamins and Hormones, Vol. 49, pp. 433-502. New York: Academic Press, 1994.
47. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell. Biol., 124: 1-6, 1994.
48. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl Cancer Inst., 85: 1657-1669, 1993.